Cysteine residues in CUB-1 domain are critical for ADAMTS13 secretion and stability

Summary

Upon stimulation, endothelial cells release von Willebrand factor (VWF) enriched in ultra-large (UL) forms that are rapidly cleaved by ADAMTS13. The zinc metalloprotease fits in the consensus for members of the ADAMTS family, but also contains two unique C-terminal CUB domains. There are five and two cysteine residues in the CUB-1 and CUB-2 domains, respectively, instead of four as deducted from the consensus. In this study, we investigated the role of cysteine residues in the CUB-1 domain in ADAMTS13 synthesis and activity. CUB-1 and cysteine mutations were expressed in mammalian cell lines and examined for synthesis, secretion, stability, and VWF-cleaving activity. When expressed as an isolated domain, CUB-1, but not CUB-2, covalently aggregated. Converting any of the four cysteines that fit in the CUB consensus (C1192, C1213, C1236 and C1254) reduced the secretion of the mutants to the conditioned medium, but not to extracellular matrix. The mutations also resulted in a moderate increase in proteolytic degradation and decrease in cleaving VWF under static, but not flowing conditions. In contrast, replacing C1275, which was found to be in the thiol form, with a serine residue prevented covalent aggregation of CUB-1, but had no effect on secretion and VWF-cleaving activity. C1275S was also markedly resistant to proteolytic degradation. The data illustrate the importance of consensus cysteines in the secretion and proteolytic activity of ADAMTS13. They also identify an ADAMTS-13 mutant that is resistant to proteolytic degradation, while maintaining a normal VWF-cleaving activity.

Keywords

TTP - ADAMTS13 - CUB domains - cysteine - biosynthesis - stability

• References

• 1 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Wille-brand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
• 2 Zheng X, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
• 3 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
• 4 Romero A, Romao MJ, Varela PF. et al. The crystal structures of two spermadhe-sins reveal the CUB domain fold. Nat Struct Biol 1997; 04: 783-788.
• 5 Bork P, Beckmann G. The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol 1993; 231: 539-545.
• 6 Feinberg H, Uitdehaag JC, Davies JM. et al. Crystal structure of the CUB1-EGFCUB2 region of mannose-binding protein associated serine protease-2. EMBO J 2003; 22: 2348-2359.
• 7 Abdul AA, Gunasekaran K, Volanakis JE. et al. The structure of complement C3b provides insights into complement activation and regulation. Nature 2006; 444: 221-225.
• 8 Tao Z, Peng Y, Nolasco L. et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106: 4139-4145.
• 9 Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280: 21773-21778.
• 10 Zhang P, Pan W, Rux AH. et al. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110: 1887-1894.
• 11 Licht C, Stapenhorst L, Simon T. et al. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/ HUS). Kidney Int 2004; 66: 955-958.
• 12 Pimanda JE, Maekawa A, Wind T. et al. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004; 103: 627-629.
• 13 Assink K, Schiphorst R, Allford S. et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-1999.
• 14 Riksen NP, Luken BM, Klasen IS. et al. Antibodies against the CUB1–2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship. Haematologica 2007; 92: e74-e76.
• 15 Tao Z, Wang Y, Choi H. et al. Cleavage of ultra-large multimers of Von Willebrand factor by C-terminal truncated mutants of ADAMTS-13 under flow. Blood 2005; 106: 141-143.
• 16 Zheng X, Nishio K, Majerus EM. et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 30136-30141.
• 17 Shang D, Zheng XW, Niiya M. et al. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108: 2207-2215.
• 18 Tao Z, Anthony K, Peng Y. et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 04: 1931-1935.
• 19 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
• 20 Dong JF, Moake JL, Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
• 21 Choi H, Aboulfatova K, Pownall HJ. et al. Shear-induced disulfide bond formation regulates adhesion activity of von willebrand factor. J Biol Chem 2007; 282: 35604-35611.
• 22 Yammani RR, Seetharam S, Seetharam B. Identification and characterization of two distinct ligand binding regions of cubilin. J Biol Chem 2001; 276: 44777-44784.
• 23 Dong JF, Li CQ, Sae-Tung G. et al. The cytoplasmic domain of glycoprotein (GP) Ibalpha constrains the lateral diffusion of the GP Ib-IX complex and modulates von Willebrand factor binding. Biochemistry 1997; 36: 12421-12427.
• 24 Majerus EM, Zheng X, Tuley EA. et al. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003; 278: 46643-46648.
• 25 Crawley JT, Lam JK, Rance JB. et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-1093.
• 26 Sieron AL, Tretiakova A, Jameson BA. et al. Structure and function of procollagen C-proteinase (mTolloid) domains determined by protease digestion, circular dichroism, binding to procollagen type I, and computer modeling. Biochemistry 2000; 39: 3231-3239.
• 27 Hintze V, Howel M, Wermter C. et al. The interaction of recombinant subdomains of the procollagen C-proteinase with procollagen I provides a quantitative explanation for functional differences between the two splice variants, mammalian tolloid and bone morphogenetic protein 1. Biochemistry 2006; 45: 6741-6748.
• 28 Turner N, Nolasco L, Tao Z. et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb. Haemost 2006; 04: 1396-1404.
• 29 Furlan M, Robles R, Morselli B. et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 8-13.